This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Inverness Diagnosed as New Buy

This Action Alerts PLUS alert was originally sent to subscribers on June 19 at 10:53 a.m. EDT. It's being republished as a bonus for readers.

Even though I've added several new stocks to the portfolio in the last month, I still have plenty of new ideas that I've been watching for a while. One of those, Inverness Medical Innovations (IMA), has pulled back recently after a nice run -- it's trading around $49.28 as I write this -- and I want to use this opportunity to initiate a position.

After you read this Alert, I'll make my first purchase in the name by picking up 1,000 shares. As always, I will look to add to my position as the opportunity to improve my cost basis comes up. My goal is grow Inverness to 4%-5% of the portfolio.

Inverness is a health care diagnostics company, both professional and in-home, as well as a manufacturer of vitamins and nutritional supplements. The vitamins business provides the company with a stable revenue stream.

But what excites me are the incredible opportunities for Inverness in the diagnostics field. The company has recently agreed to acquire two companies -- Biosite (BSTE) and Cholestech (CTEC) -- that will drastically improve the company's product portfolio and distribution capabilities, specifically in the fast-growing cardiology diagnostic market.

The deals also offer incredible financial synergies from both a cost-cutting and revenue perspective. The Biosite transaction alone could prove to add more than 50 cents to 2008 earnings. Cholestech should add 5 cents to 10 cents to 2008 earnings.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PG $81.25 0.06%
TSLA $151.04 -7.10%
YHOO $26.78 -4.30%
AAPL $94.58 0.60%
FB $100.33 -3.60%


Chart of I:DJI
DOW 15,879.84 -325.13 -2.01%
S&P 500 1,835.82 -44.23 -2.35%
NASDAQ 4,239.5010 -123.6430 -2.83%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs